Mount Sinai Surgery Chief Announces Breakthrough in Trifecta Cancer Treatment

Dr. David B. Samadi, M.D. announces Trifecta Breakthrough, launching a new era in prostate cancer treatment and cure with quick recovery and minimal post operative complications

New York, NY (PRWEB) April 23, 2008 -- David B. Samadi, M.D. Chief of Robotics and Minimal Invasive Surgery at Mount Sinai Medical School in New York City is at the forefront of a revolutionary breakthrough in prostate cancer treatment which brings new hope to patients requiring oncological surgeries. Technological advancements in precision robotics have progressed the field of oncology to allow for the skill of a surgeon's hand to be translated through a robotic arm. This method requires a significantly smaller incision than previous methods, and significantly reduces the odds of infection and other complications. The results speak for themselves, with over 1,350 robotic prostate surgeries to his credit; Dr. Samadi has a growing following of grateful patients to give testimony to the procedure.

The advancements in da Vinci surgery launches a new era in prostate cancer treatment characterized by the emergence of a "Trifecta" treatment model. This is the overlap of three distinct FDA approved surgical treatment options - traditional open surgery, less invasive laparoscopic and robotic surgery - that give cancer patients more options than ever before to fight this infamous disease. Dr. Samadi is amongst the handful of surgeons skilled in all three procedures and takes care to explain the pros and cons of each option to all of his patients. "I don't believe in surprising my patients and I am confident in my ability to provide the best prostate cancer treatment in the world," said Dr. Samadi.

A second "Trifecta" is responsible for a more precise method of evaluating the success of prostate cancer surgeries. This is the overlap of three criteria: cancer cure, continence and potency. These important post-operative surgical goals are the cornerstone of Dr. Samadi's practice. Samadi's philosophy is that it is not enough for a patient to see improvements in one or two of these areas, true success can only be measured, using all three criteria.

Dr. Samadi also attributes the success of his procedures to his expert surgical team - from scrub nurses to anesthesiologists - reiterating that successful surgery is a team effort. While breakthroughs in medical robotics may give glimpse to the future of oncology, Dr. Samadi is quick to point out that the traditional methods still have their place in cancer treatment. An effective treatment program is going to assess the individual to determine the optimal surgical method. "It's great to have access to stare-of-the-art medical technology, but there is no substitute for proven open and laparoscopic surgical skills," said Dr. Samadi.

Dr. Samadi is a board certified Urologic Oncologist, specializing in the diagnosis and treatment of bladder, kidney and prostate cancer using minimally invasive methods. Dr. Samadi utilizes the DaVinci robotic surgical system for his robotic procedures. For more information visit Dr. Samadi’s website www.roboticoncology.com

###
Contact Information
David B. Samadi, M.D.
Robotic Oncology
http://www.roboticoncology.com
212-241-8779

Online Web 2.0 Version
You can read the online version of this press release here.